GlassScriptPhysician profile
Allan Crimm
NPI 1720089170
$6,240.21
in general payments reported to CMS, 2019-2025
44 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,934 · 2020: $335 · 2021: $36.12 · 2022: $61.97 · 2023: $739 · 2024: $1,775 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,872 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,872.06 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $990.09 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $920.35 | 2019-2025 | |
| Abbvie INC. | $669.61 | 2023-2025 | Ubrelvy, Linzess, Viberzi |
| Astellas Pharma US INC | $466.93 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $370.39 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $245.78 | 2019-2025 | Evenity, Repatha, Otezla |
| Amarin Pharma, INC. | $234.06 | 2019-2020 | |
| Gilead Sciences, INC. | $218.98 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.11 | 2019-2025 | Synjardy, Jardiance, Tradjenta |
| Lilly USA, LLC | $197.98 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.90 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $136.85 | 2019-2025 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $118.93 | 2019-2025 | Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $100.84 | 2023-2025 | Inspire |
| Eisai INC. | $95.11 | 2023-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Crimm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.